Yağmur Bayındır
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yağmur Bayındır has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Seza Ozen
Department of Pediatrics, Hacettepe University, Ankara, Turkey
15 shared publications - Ezgi Deniz Batu
Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University School of Medicine , Ankara
7 shared publications - Yelda Bilginer
Department of Pediatric Rheumatology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
7 shared publications - Zeynep Balık
Department of Pediatric Rheumatology, Faculty of Medicine, Hacettepe University, Ankara, Türkiye
7 shared publications - Emil Aliyev
Division of Rheumatology, Department of Paediatrics, Hacettepe University Faculty of Medicine , Ankara
5 shared publications - Özge Başaran
Division of Rheumatology, Department of Paediatrics, Hacettepe University Faculty of Medicine , Ankara
5 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 68 (5) , 845-854
Exploratory epigenetic analysis of host gene–dependent regulation of miR-197-3p in familial Mediterranean fever
Background. Familial Mediterranean Fever (FMF) is an autosomal recessive autoinflammatory disease caused by mutations in the Mediterranean Fever (MEFV) gene. Despite its monogenic basis, FMF shows marked clinical heterogeneity, suggesting additional regulatory mechanisms. This exploratory study aimed to investigate host gene–dependent mechanisms underlying altered miR-197-3p expression in FMF. Materials and Methods. Peripheral blood mononuclear cells from homozygous FMF patients (n=6) and matched healthy controls (n=6) were analyzed. miR-197-3p expression was quantified using RT-qPCR. DNA methylation patterns in regulatory regions of the GNAI3 promoter and the MIR197 upstream candidate regulatory region were assessed by bisulfite sequencing. Results. miR-197-3p expression was significantly reduced in FMF patients compared with controls, as expected. No evidence supporting regulation through the MIR197 upstream candidate regulatory region was observed. Differential methylation within the GNAI3 promoter was statistically significant (p = 0.0093), supporting biological relevance despite the limited cohort size. Conclusion. These pilot findings provide preliminary molecular evidence supporting host gene–dependent regulation of miR-197-3p in FMF. Given the small cohort size, these findings should be considered exploratory and require validation in larger, independent cohorts.
- 27 October 2026
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 68 (5) , 845-854
Open AccessExploratory epigenetic analysis of host gene–dependent regulation of miR-197-3p in familial Mediterranean fever
Background. Familial Mediterranean Fever (FMF) is an autosomal recessive autoinflammatory disease caused by mutations in the Mediterranean Fever (MEFV) gene. Despite its monogenic basis, FMF shows marked clinical heterogeneity, suggesting additional regulatory mechanisms. This exploratory study aimed to investigate host gene–dependent mechanisms underlying altered miR-197-3p expression in FMF. Materials and Methods. Peripheral blood mononuclear cells from homozygous FMF patients (n=6) and matched healthy controls (n=6) were analyzed. miR-197-3p expression was quantified using RT-qPCR. DNA methylation patterns in regulatory regions of the GNAI3 promoter and the MIR197 upstream candidate regulatory region were assessed by bisulfite sequencing. Results. miR-197-3p expression was significantly reduced in FMF patients compared with controls, as expected. No evidence supporting regulation through the MIR197 upstream candidate regulatory region was observed. Differential methylation within the GNAI3 promoter was statistically significant (p = 0.0093), supporting biological relevance despite the limited cohort size. Conclusion. These pilot findings provide preliminary molecular evidence supporting host gene–dependent regulation of miR-197-3p in FMF. Given the small cohort size, these findings should be considered exploratory and require validation in larger, independent cohorts.
- Open Access
- 1 September 2026
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
Comparison of the Clinical Expression of Patients with Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis (E/SpRJIA) from Türkiye and India
Background/Aims: To compare the clinical characteristics of enthesitis/ spondylitis-related juvenile idiopathic arthritis (E/SpRJIA), a relatively prevalent JIA subtype in Türkiye and India, and to explore potential populationspecific differences in disease expression. Materials and Methods: This multicenter, binational, retrospective cohort study included children fulfilling the provisional PRINTO classification criteria for E/SpRJIA from 12 pediatric rheumatology centers in Türkiye and India. Demographic characteristics, clinical manifestations, human leukocyte antigen B27 (HLA-B27) status, laboratory findings, disease course, and treatment-related data were collected. A multivariable logistic regression analysis was performed to identify factors independently associated with sacroiliitis at diagnosis. Results: A total of 498 patients were included (391 Turkish and 107 Indian). At disease onset, peripheral polyarticular involvement was more common in Indian patients (40.2% vs 5.6%), whereas axial involvement was more frequent in Turkish patients (45.8% vs 18.7%). HLA-B27 positivity was higher in Indian patients than in Turkish patients (79.5% vs 56.4%). During follow-up, sacroiliitis, enthesitis, and tarsitis were more common among Turkish patients, while peripheral arthritis and dactylitis were more frequent among Indian patients. NSAIDs were used more frequently in India, whereas conventional and biologic DMARDs were more commonly used in Türkiye. In multivariable analysis, country of origin remained independently associated with sacroiliitis at diagnosis, whereas HLA-B27 positivity did not. Conclusion: E/SpRJIA demonstrates substantial phenotypic heterogeneity between Turkish and Indian populations. Turkish patients exhibited a predominantly axial disease pattern, whereas Indian patients more commonly showed peripheral polyarticular involvement despite higher HLA-B27 positivity. These findings suggest that factors beyond HLA-B27, including broader genetic, environmental, and population-specific influences, may contribute to differences in disease expression. Further prospective and genetically informed studies are needed to clarify the determinants of this heterogeneity. Cite this article as: İşgüder R, Sharma A, Kızıldağ Z, et al. Comparison of the Clinical Expression of Patients with Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis (E/SpRJIA) from Türkiye and India. ArchRheumatol. Published online September 1, 2026. doi: 10.5152/ArchRheumatol.2026.25122.
- 1 September 2026
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
Open AccessComparison of the Clinical Expression of Patients with Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis (E/SpRJIA) from Türkiye and India
Background/Aims: To compare the clinical characteristics of enthesitis/ spondylitis-related juvenile idiopathic arthritis (E/SpRJIA), a relatively prevalent JIA subtype in Türkiye and India, and to explore potential populationspecific differences in disease expression. Materials and Methods: This multicenter, binational, retrospective cohort study included children fulfilling the provisional PRINTO classification criteria for E/SpRJIA from 12 pediatric rheumatology centers in Türkiye and India. Demographic characteristics, clinical manifestations, human leukocyte antigen B27 (HLA-B27) status, laboratory findings, disease course, and treatment-related data were collected. A multivariable logistic regression analysis was performed to identify factors independently associated with sacroiliitis at diagnosis. Results: A total of 498 patients were included (391 Turkish and 107 Indian). At disease onset, peripheral polyarticular involvement was more common in Indian patients (40.2% vs 5.6%), whereas axial involvement was more frequent in Turkish patients (45.8% vs 18.7%). HLA-B27 positivity was higher in Indian patients than in Turkish patients (79.5% vs 56.4%). During follow-up, sacroiliitis, enthesitis, and tarsitis were more common among Turkish patients, while peripheral arthritis and dactylitis were more frequent among Indian patients. NSAIDs were used more frequently in India, whereas conventional and biologic DMARDs were more commonly used in Türkiye. In multivariable analysis, country of origin remained independently associated with sacroiliitis at diagnosis, whereas HLA-B27 positivity did not. Conclusion: E/SpRJIA demonstrates substantial phenotypic heterogeneity between Turkish and Indian populations. Turkish patients exhibited a predominantly axial disease pattern, whereas Indian patients more commonly showed peripheral polyarticular involvement despite higher HLA-B27 positivity. These findings suggest that factors beyond HLA-B27, including broader genetic, environmental, and population-specific influences, may contribute to differences in disease expression. Further prospective and genetically informed studies are needed to clarify the determinants of this heterogeneity. Cite this article as: İşgüder R, Sharma A, Kızıldağ Z, et al. Comparison of the Clinical Expression of Patients with Enthesitis/Spondylitis-Related Juvenile Idiopathic Arthritis (E/SpRJIA) from Türkiye and India. ArchRheumatol. Published online September 1, 2026. doi: 10.5152/ArchRheumatol.2026.25122.
- 6 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Paediatric neuro-Behçet’s disease: multi-centre observational study
Objectives: Behçet’s disease (BD) is a multisystemic inflammatory disease, and its neurologic involvement represents serious manifestations. This study aimed to elucidate the neurologic manifestations of BD in a large paediatric population and to describe its outcomes and prognosis. Methods: This retrospective multicentre study included 75 paediatric patients diagnosed with neuro-Behçet’s disease (NBD). Demographic data, clinical features, neuroimaging findings, treatments and disability conditions were reviewed. Results: Neurologic manifestations were observed in 52 patients (69.3%) at initial presentation and in 23 patients (30.7%) at a median of 14 months (8–30) after diagnosis. The distribution of NBD subgroups was as follows: 56 patients (74.7%) with nonparenchymal, 15 patients (20%) with parenchymal and 4 patients (5.3%) with mixed forms. Headache, observed in 70 patients (93.3%), was the most common neurological symptom, being significantly more frequent in the non-parenchymal form (P = 0.028). Paresis, sensory loss and mood/mental health problems were significantly more frequent in the parenchymal form (P = 0.034, P = 0.016, P = 0.005, respectively). Neuroimaging revealed parenchymal lesions in 19 patients (25.3%), and vascular lesions were in 55 patients (73.3%). Azathioprine was the most commonly used immunosuppressor therapy (78.7%). The median follow-up duration of patients was 30 months (17.5–52.5), during which significant clinical improvement was observed, with no deaths reported. Conclusion: Paediatric NBD remains a significant issue in paediatric rheumatology. The non-parenchymal subgroup is the predominant form in children. Paediatric NBD should be confirmed and classified by MRI. The early aggressive immunosuppressive therapy provides clinical improvement. Activity and disability indexes are valuable for treatment and follow-up.
- 6 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Paediatric neuro-Behçet’s disease: multi-centre observational study
Objectives: Behçet’s disease (BD) is a multisystemic inflammatory disease, and its neurologic involvement represents serious manifestations. This study aimed to elucidate the neurologic manifestations of BD in a large paediatric population and to describe its outcomes and prognosis. Methods: This retrospective multicentre study included 75 paediatric patients diagnosed with neuro-Behçet’s disease (NBD). Demographic data, clinical features, neuroimaging findings, treatments and disability conditions were reviewed. Results: Neurologic manifestations were observed in 52 patients (69.3%) at initial presentation and in 23 patients (30.7%) at a median of 14 months (8–30) after diagnosis. The distribution of NBD subgroups was as follows: 56 patients (74.7%) with nonparenchymal, 15 patients (20%) with parenchymal and 4 patients (5.3%) with mixed forms. Headache, observed in 70 patients (93.3%), was the most common neurological symptom, being significantly more frequent in the non-parenchymal form (P = 0.028). Paresis, sensory loss and mood/mental health problems were significantly more frequent in the parenchymal form (P = 0.034, P = 0.016, P = 0.005, respectively). Neuroimaging revealed parenchymal lesions in 19 patients (25.3%), and vascular lesions were in 55 patients (73.3%). Azathioprine was the most commonly used immunosuppressor therapy (78.7%). The median follow-up duration of patients was 30 months (17.5–52.5), during which significant clinical improvement was observed, with no deaths reported. Conclusion: Paediatric NBD remains a significant issue in paediatric rheumatology. The non-parenchymal subgroup is the predominant form in children. Paediatric NBD should be confirmed and classified by MRI. The early aggressive immunosuppressive therapy provides clinical improvement. Activity and disability indexes are valuable for treatment and follow-up.
- 5 March 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 78, 152956
Evaluation of disease severity and treatment responses in patients with enthesitis-related arthritis
- 5 March 2026
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 78, 152956
Evaluation of disease severity and treatment responses in patients with enthesitis-related arthritis
- 4 December 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 195, 112599
Predictive role of muscle MRI in juvenile dermatomyositis: A tertiary center experience
- 4 December 2025
- Published by Elsevier in European Journal of Radiology
- Vol. 195, 112599
Predictive role of muscle MRI in juvenile dermatomyositis: A tertiary center experience
- Open Access
- 2 September 2025
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 23 (1) , 1-26
Neurological involvement in children with familial Mediterranean fever: a systematic review
Although typical findings of familial Mediterranean fever (FMF), such as brief fever episodes and abdominal or chest pain, have been largely described, little is known about the neurological manifestations of the disease in childhood. A systematic search of the literature was conducted in PubMed/Medline, Cochrane, and Web of Science databases in accordance with the PRISMA guidelines, using MeSH terms related to FMF and neurological manifestations. Studies involving patients under 18 years of age diagnosed with FMF with neurological manifestations were included. Sixty-four studies, comprising 4753 children with FMF, were included. Approximately 33.9% of them had some degree of neurological involvement. Headache was the most common neurological symptom and was often associated with FMF flares, with frequencies ranging from 4.8 to 58.8%. Febrile seizures were also relevant manifestations, as expected in children with FMF since they have more and more high fever during childhood, with frequencies ranging from 1 to 15.2%. Demyelinating disorders, such as multiple sclerosis, were rarely reported, mostly in female adolescents with the homozygous M694V MEFV genotype. A few studies have shown that cochlear and retinal involvement due to chronic and recurrent inflammation may contribute to sensorineural hearing loss and retinal abnormalities. Although causality has not been shown and reporting bias cannot be excluded, neurological involvement appears relatively common in children with FMF and may lead to long-term disability and reduced quality of life. These findings support the need for a comprehensive neurological assessment to enable early detection, appropriate management, and better long-term outcomes.
- 2 September 2025
- Published by Springer Nature in Pediatric Rheumatology
- Vol. 23 (1) , 1-26
Open AccessNeurological involvement in children with familial Mediterranean fever: a systematic review
Although typical findings of familial Mediterranean fever (FMF), such as brief fever episodes and abdominal or chest pain, have been largely described, little is known about the neurological manifestations of the disease in childhood. A systematic search of the literature was conducted in PubMed/Medline, Cochrane, and Web of Science databases in accordance with the PRISMA guidelines, using MeSH terms related to FMF and neurological manifestations. Studies involving patients under 18 years of age diagnosed with FMF with neurological manifestations were included. Sixty-four studies, comprising 4753 children with FMF, were included. Approximately 33.9% of them had some degree of neurological involvement. Headache was the most common neurological symptom and was often associated with FMF flares, with frequencies ranging from 4.8 to 58.8%. Febrile seizures were also relevant manifestations, as expected in children with FMF since they have more and more high fever during childhood, with frequencies ranging from 1 to 15.2%. Demyelinating disorders, such as multiple sclerosis, were rarely reported, mostly in female adolescents with the homozygous M694V MEFV genotype. A few studies have shown that cochlear and retinal involvement due to chronic and recurrent inflammation may contribute to sensorineural hearing loss and retinal abnormalities. Although causality has not been shown and reporting bias cannot be excluded, neurological involvement appears relatively common in children with FMF and may lead to long-term disability and reduced quality of life. These findings support the need for a comprehensive neurological assessment to enable early detection, appropriate management, and better long-term outcomes.
- Open Access
Performance in adults of the EULAR/PRINTO/PRES (Ankara 2008) classification criteria for IgA vasculitis
Objective: To examine the performance in adults of the European Alliance of Associations for Rheumatology (EULAR)/Pediatric Rheumatology European Society (PReS)-endorsed Ankara 2008 classification criteria for IgA vasculitis (IgAV). Methods: The EULAR/PReS/Ankara 2008 classification criteria for IgAV were applied to patients enrolled in an international observational cohort which included patients with IgAV and comparators with other forms of small-vessel and medium-vessel vasculitis. After the initial assessment of the performance of the criteria, possible revisions to increase the performance were tested. The revised criteria were then assessed in an independent validation cohort within a multicentre Turkish vasculitis registry. Results: The dataset consisted of 178 IgAV cases and 1705 comparators. The Ankara 2008 criteria require skin involvement plus one of the following four criteria: abdominal pain, a biopsy showing IgA deposition, arthritis or arthralgia, or renal involvement (any haematuria and/or proteinuria). The specificity of the criteria improved when a positive test for anti-neutrophil cytoplasmic autoantibody or blood cryoglobulins was considered an exclusion criterion. The revised criteria had a sensitivity of 76.4% (95% CI 69.8% to 82.2%) and a specificity of 94.5% (95.0% CI 93.4% to 95.1%). In the validation set, the sensitivity and specificity of the revised criteria were 97.8% (95% CI 94.0% to 99.0%) and 85.0% (95.0% CI 78.0% to 90.0%), respectively. Conclusion: The revised EULAR/PReS-endorsed Ankara 2008 IgAV classification criteria perform well in adults with IgAV and are appropriate for use in clinical research.
Open AccessPerformance in adults of the EULAR/PRINTO/PRES (Ankara 2008) classification criteria for IgA vasculitis
Objective: To examine the performance in adults of the European Alliance of Associations for Rheumatology (EULAR)/Pediatric Rheumatology European Society (PReS)-endorsed Ankara 2008 classification criteria for IgA vasculitis (IgAV). Methods: The EULAR/PReS/Ankara 2008 classification criteria for IgAV were applied to patients enrolled in an international observational cohort which included patients with IgAV and comparators with other forms of small-vessel and medium-vessel vasculitis. After the initial assessment of the performance of the criteria, possible revisions to increase the performance were tested. The revised criteria were then assessed in an independent validation cohort within a multicentre Turkish vasculitis registry. Results: The dataset consisted of 178 IgAV cases and 1705 comparators. The Ankara 2008 criteria require skin involvement plus one of the following four criteria: abdominal pain, a biopsy showing IgA deposition, arthritis or arthralgia, or renal involvement (any haematuria and/or proteinuria). The specificity of the criteria improved when a positive test for anti-neutrophil cytoplasmic autoantibody or blood cryoglobulins was considered an exclusion criterion. The revised criteria had a sensitivity of 76.4% (95% CI 69.8% to 82.2%) and a specificity of 94.5% (95.0% CI 93.4% to 95.1%). In the validation set, the sensitivity and specificity of the revised criteria were 97.8% (95% CI 94.0% to 99.0%) and 85.0% (95.0% CI 78.0% to 90.0%), respectively. Conclusion: The revised EULAR/PReS-endorsed Ankara 2008 IgAV classification criteria perform well in adults with IgAV and are appropriate for use in clinical research.
- 1 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (Supplement) , i131-i133
Highlights from the breakout session: vasculitis in paediatric rheumatology
The 21st International Vasculitis Workshop, held in Barcelona, Spain, from April 7 to 10, 2024, highlighted advances in pediatric vasculitis, focusing on a holistic, multidisciplinary approach. Common childhood vasculitides, including IgA Vasculitis (IgAV) and Kawasaki Disease (KD), were discussed. The Ankara 2008 criteria for IgAV, endorsed by EULAR and PReS, were evaluated for their performance in adults, showing high sensitivity but necessitating further refinement for improved specificity. Studies on genetic associations, such as Human Leukocyte Antigen (HLA) polymorphisms in IgAV, and biomarkers like S100A8/A9, HMGB1, and RAGE, were presented. Kawasaki disease research included novel anti-apolipoprotein A-2 antibodies, showing promise in reducing coronary arteritis. Monogenic vasculitides, such as deficiency of ADA2, were addressed with new consensus-driven recommendations. The workshop underscored the importance of continued research and tailored therapeutic strategies to improve outcomes in pediatric vasculitis, paving the way for advancements in diagnosis, management, and understanding of these complex diseases.
- 1 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (Supplement) , i131-i133
Highlights from the breakout session: vasculitis in paediatric rheumatology
The 21st International Vasculitis Workshop, held in Barcelona, Spain, from April 7 to 10, 2024, highlighted advances in pediatric vasculitis, focusing on a holistic, multidisciplinary approach. Common childhood vasculitides, including IgA Vasculitis (IgAV) and Kawasaki Disease (KD), were discussed. The Ankara 2008 criteria for IgAV, endorsed by EULAR and PReS, were evaluated for their performance in adults, showing high sensitivity but necessitating further refinement for improved specificity. Studies on genetic associations, such as Human Leukocyte Antigen (HLA) polymorphisms in IgAV, and biomarkers like S100A8/A9, HMGB1, and RAGE, were presented. Kawasaki disease research included novel anti-apolipoprotein A-2 antibodies, showing promise in reducing coronary arteritis. Monogenic vasculitides, such as deficiency of ADA2, were addressed with new consensus-driven recommendations. The workshop underscored the importance of continued research and tailored therapeutic strategies to improve outcomes in pediatric vasculitis, paving the way for advancements in diagnosis, management, and understanding of these complex diseases.
- Open Access
- 27 February 2025
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 67 (1) , 61-68
Treatment of systemic juvenile idiopathic arthritis: conventional treatment versus biologics
Objective. We aimed to identify and compare systemic juvenile idiopathic arthritis (sJIA) patients receiving treatment with either glucocorticoids and/or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or biologic drugs. Methods. This was a retrospective cross-sectional study. sJIA patients (n=138) were categorized into two groups: Group A (n=51) consisted of individuals who received only glucocorticoids and/or csDMARDs, while Group B (n=87) included those who received at least one biologic drug. Results. Group B patients exhibited a higher prevalence of macrophage activation syndrome (MAS) (p=0.001) at presentation. C-reactive protein (CRP) levels and systemic Juvenile Arthritis Disease Activity Scores (sJADAS) at diagnosis were significantly higher in Group B (p
- 27 February 2025
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 67 (1) , 61-68
Open AccessTreatment of systemic juvenile idiopathic arthritis: conventional treatment versus biologics
Objective. We aimed to identify and compare systemic juvenile idiopathic arthritis (sJIA) patients receiving treatment with either glucocorticoids and/or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or biologic drugs. Methods. This was a retrospective cross-sectional study. sJIA patients (n=138) were categorized into two groups: Group A (n=51) consisted of individuals who received only glucocorticoids and/or csDMARDs, while Group B (n=87) included those who received at least one biologic drug. Results. Group B patients exhibited a higher prevalence of macrophage activation syndrome (MAS) (p=0.001) at presentation. C-reactive protein (CRP) levels and systemic Juvenile Arthritis Disease Activity Scores (sJADAS) at diagnosis were significantly higher in Group B (p
- Open Access
- 18 February 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (1) , 348
Erratum to “ Telemedicine in pediatric rheumatology: the video pediatric gait, arms, legs, and spine (v-pGALS) examination” [Turkish Journal of Medical Sciences 54 (5) 2024 963-969 ]
This erratum is written to correct an error in our previous publication. Supplement Figure 2 was published incorrectly as one page instead of six. DOI of original article: https://doi.org/10.55730/1300-0144.5874
- 18 February 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (1) , 348
Open AccessErratum to “ Telemedicine in pediatric rheumatology: the video pediatric gait, arms, legs, and spine (v-pGALS) examination” [Turkish Journal of Medical Sciences 54 (5) 2024 963-969 ]
This erratum is written to correct an error in our previous publication. Supplement Figure 2 was published incorrectly as one page instead of six. DOI of original article: https://doi.org/10.55730/1300-0144.5874